Navigation Links
May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO

Data support proteomic test as a predictor of overall survival benefit with EGFRI treatment

BROOMFIELD, Colo., May 14 /PRNewswire/ -- Data on VeriStrat, a blood-based, proteomic test currently used for patients with advanced stage non-small-cell lung cancer (NSCLC), will be presented by Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University on Monday, June 1st at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a 314 patient study indicate that VeriStrat is predictive of survival benefit in patients with squamous cell carcinoma of the head and neck (SCCHN) treated with epidermal growth factor inhibitors (EGFRIs). According to the data, VeriStrat provides information to help oncologists identify patients most likely to benefit from EGFRI therapy.

In the study, VeriStrat was used to classify outcomes in patients with SCCHN who were treated with gefitinib (G), erlotinib and bevacizumab (E/B), cetuximab (C), or palliative chemotherapy (PC). Gefitinib, erlotinib and cetuximab are EGFRIs with activity in SCCHN. Results from the study show that among patients treated with EGFRIs, VeriStrat predicted an overall survival benefit (G: p=0.007, HR 0.41; E/B: p=0.02, HR 0.20; C: p=0.06, HR-0.26). VeriStrat did not classify survival outcomes in patients treated with palliative chemotherapy (PC: p=0.76, HR 0.88).

"At present, there are no validated diagnostic tests to guide therapy selection for patients with SCCHN. Having a blood test that provides results which will help oncologists decide whether or not to treat head and neck cancer patients with anti-EGFR agents would be a major advancement in the treatment of this disease," stated Ezra Cohen, MD, Associate Professor of Medicine at the University of Chicago and a study investigator.

The data support previous study results in which VeriStrat effectively identified patients with NSCLC who were likely to have good or poor outcomes following treatment with EGFRIs (J Natl Cancer Inst. 2007;99(11):838-46). Additional studies are underway to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other EGFRIs.

A study reporting results evaluating the association of VeriStrat status and genetic features with survival after treatment with erlotinib in patients with NSCLC will also be presented on Saturday, May 30th. For more information on the time and locations of these presentations, visit

"The data to be presented at ASCO validate our molecular profiling approach to identify patient populations who are most likely to benefit from targeted therapies as well as those who are unlikely to receive any benefit," said Heinrich Roder, D.Phil., Chief Technical Officer at Biodesix. "Biodesix is committed to advancing personalized medicine as we continue our research in identifying the relationship between disease, mass spectrometry profiles and therapies. The data from ASCO, coupled with our previous research, show that VeriStrat is effective at predicting outcomes to therapeutics affecting the EGFR pathway, independent of their specific mode of action, and for tumor types where this is a targeted pathway. This brings us one step closer to a healthcare model that is highly personalized."

About VeriStrat: VeriStrat is a pretreatment serum, proteomic test for patients with advanced NSCLC. The test identifies patients who are likely to have good or poor outcomes after treatment with EGFRIs. Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat has been validated in clinical studies with over 1000 patients. Biodesix is engaging in additional studies to further validate the test and to explore the clinical utility of VeriStrat in other solid epithelial tumors and with other EGFRIs. For more information on VeriStrat or to order VeriStrat, visit or call the VeriStrat Support Hotline at 1-866-432-5930.

About Biodesix: Biodesix is a fully integrated molecular diagnostic company enabling personalized medicine using mass spectrometry-based molecular profiling. Working with academic and biopharma collaborators, Biodesix uses its proprietary technology, ProTS(R), to discover and validate diagnostic tests that improve patient outcomes. Biodesix' first product, VeriStrat, is commercially available for physicians to help guide their treatment of patients with non-small cell lung cancer. For more information on Biodesix, visit

This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.

SOURCE Biodesix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
2. ESA to Launch Corona(R) ultra(TM) at Pittcon 2009: Booth #1080
3. Hospital Build Asia Exhibition and Congress 2009: Regions Most Comprehensive Healthcare Infrastructure Planning and Development Event to Debut in Singapore
4. National Heart Failure Awareness Week February 8-14, 2009: Visit to Learn More About Heart Failure
5. Lower Your Grocery Bill, Improve Health In 2009: Top Tips From Dr. Praegers Sensible Foods
6. Pharmacy Technician Certification Board (PTCB) Unveils New Testing Features for 2009: PTCB Exam to be Offered Daily; Test Results Given to Candidates Immediately in 2009
7. 2009: The Year of Health Care Reform? Faith-Based Investors See Doubling of Related Shareholder Resolutions, Growing Public Support From Corporate America
8. Nutrition Software nutrinote 2009: Lose Weight With the Help of a Computer
9. NewCardio to Present at OneMedForum 2009: Disrupters and Drivers on January 13 in San Francisco
10. OneMedPlace announces panels for "OneMedForum 2009: Disrupters and Drivers in Eight Areas of Medical Technology" -- CEOs and investors to meet in unique format of focused sessions
11. SAGE launching new sports medicine journal in 2009: Sports Health: A Multidisciplinary Approach
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
(Date:11/24/2015)... ... 2015 , ... Genesis Chiropractic Software helps practice owners automate ... between the practice owner and the patient that automatically manages all five aspects ... Click here to learn more. , According to Dr. Brian ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish ... referral for dental implants at her Mississauga, ON practice. Dr. Williams has ... the placement of dental implants. , Missing teeth can lead to a variety ...
(Date:11/24/2015)... FRANCISCO, CA (PRWEB) , ... November 24, 2015 ... ... half-cup sizes, has launched their Black Friday sale a week early, offering 40% ... continues to transform the intimate apparel industry through both mobile fit technology and ...
(Date:11/24/2015)... ... November 24, 2015 , ... DMG Productions announced that they will feature ... quarter 2016 via Discovery Channel. Dates and show times TBA. , Aphria, Inc., is ... the business of producing and supplying medical marijuana pursuant to the Marijuana for Medical ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... November 25, 2015 ... addition of the  "Global Drug Device ... to their offering.  --> ... of the  "Global Drug Device Combination ... their offering.  --> Research ...
(Date:11/24/2015)... 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" or ... R&D capability and technology platform company serving the pharmaceutical, ... China and the United ... general meeting of shareholders held today, the Company,s shareholders ... approve the previously announced agreement and plan of merger ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
Breaking Medicine Technology: